Introduction: Patients with metastatic prostate cancer, especially in the castrate-resistant setting, have a poor prognosis. Many agents have been approved for metastatic prostate cancer, such as androgen receptor pathway inhibitors, taxane-based chemotherapy, radiopharmaceuticals, and immunotherapy. However, prostate cancer remains the leading cause of cancer deaths in nonsmoking men. Fortunately, many more novel agents are under investigation.
Areas Covered: We provide an overview of the broad group of novel therapies for metastatic prostate cancer, with an emphasis on active and recruiting clinical trials that have been recently published and/or presented at national or international meetings.
Expert Opinion: The future for patients with metastatic prostate cancer is promising, with further development of novel therapies such as radiopharmaceuticals. Based on a growing understanding of prostate cancer biology, novel agents are being designed to overcome resistance to approved therapies. There are many trials using novel agents either as monotherapy or in combination with already approved agents with potential to further improve outcomes for men with advanced prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14737140.2023.2290197 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical Study of Lymph Node Dissection in Robot-Assisted Radical Prostatectomy for High-Risk Prostate Cancer].
Hinyokika Kiyo
November 2024
The Department of Urology, Kyoto University Hospital.
We retrospectively analyzed the regions and perioperative outcomes associated with lymph node dissection in patients with prostate cancer. Of 543 patients who underwent robot-assisted radical prostatectomy for prostate cancer with or without lymph node dissection according to the modified D'Amico criteria, 333 (61.3%), 128 (23.
View Article and Find Full Text PDFVisibility of mpMRI region of interest on ultrasound during cognitive fusion targeted biopsy predicts prostate cancer detection: a prospective single-center study.
Abdom Radiol (NY)
December 2024
Peking University First Hospital, 8 Xishiku Street, Xicheng, Beijing, 100034, China.
Purpose: The purpose of this study was to evaluate the nature of ultrasound characteristics during mpMRI/TRUS cognitive fusion targeted biopsy (cTB).
Methods: From 2023 to 2024, data from 502 lesions in 426 men who underwent targeted combined systematic biopsy were analyzed. All lesions had a Prostate Imaging Reporting and Data System (PI-RADS) score of ≥ 3.
Is ipsilateral systematic biopsy combined with targeted biopsy the optimal substitute for bilateral systematic biopsy combined with targeted biopsy: A systematic review and meta-analysis.
Urol Oncol
December 2024
Department of Urology, West China Hospital, Sichuan University, Chengdu, China. Electronic address:
Background: The current standard prostate biopsy method, which combine systematic biopsy (SB) with targeted biopsy (TB), has shortcomings such as overdiagnosis and overtreatment. To evaluate the effectiveness of ipsilateral systematic biopsy (ips-SB) combined with targeted biopsy (ips-SB+TB) and contralateral SB (con-SB) combined with TB (con-SB+TB) as potential alternatives to SB+TB.
Methods: A comprehensive literature search was conducted in Cochrane, Embase, Ovid, and PubMed databases until September 2024.
[Evaluation of the Effectiveness of Bladder Ultrasound Imaging Devices in Radiation Therapy].
Nihon Hoshasen Gijutsu Gakkai Zasshi
December 2024
Department of Radiology, Tatebayashi Kosei General Hospital.
Purpose: In radiation therapy for prostate cancer, bladder ultrasound diagnostic devices are utilized. However, the performance of all devices has not been fully evaluated. This study aims to assess the effectiveness of three devices-Lilium IP200 (IP200; Lilium Otsuka, Kanagawa), CubeScan BioCon-900S (900S; JCT, Hiroshima), and BVI 6100 (BVI 6100; Verathon, Bothell, WA, USA)-as tools for measuring bladder volume.
View Article and Find Full Text PDFLong-Term Oncological Outcomes of Active Surveillance for Low-Risk Prostate Cancer Diagnosed During the MRI Era.
Fr J Urol
December 2024
Department of Urology, Univ. Lille, Lille, France. Electronic address:
Background: Active surveillance (AS) is the recommended approach for managing Grade-Group1 (GG1) prostate cancer (PCa). Incorporating MRI at entry improve patient selection and outcomes.
Objective: To evaluate long-term oncological outcomes of patients receiving AS selected with MRI at entry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!